Workshop C – Staying the Course: Addressing Compliance Challenges in the Treatment of Pediatric Leukemia


Wendy Landier, PhD, CRNP
Associate Professor, Pediatric Hematology/Oncology,
Institute for Cancer Outcomes and Survivorship,
University of Alabama at Birmingham, Birmingham, AL

Wendy Landier is a pediatric nurse practitioner who has worked in pediatric oncology for over 30 years. She holds a Master’s degree in nursing from UCLA and a PhD from the University of Hawaii. She is currently an associate Professor in the Division of Pediatric Hematology/Oncology, Institute for Cancer Outcomes and Survivorship, in the School of Medicine, and also holds a secondary appointment in the School of Nursing, at the University of Alabama at Birmingham. Her career has primarily focused on childhood leukemia, lymphoma, and cancer survivorship, and her research focuses on understanding and improving health outcomes in children with leukemia and in cancer survivors. She current serves as Chair of the Children’s Oncology Group Nursing Discipline and as co-Chair of the COG Long-Term Follow-Up Guidelines Core Committee. She has published extensively regarding adherence to therapy in childhood leukemia, late effects in childhood cancer survivors, and the provision of patient/family education for parents of newly diagnosed pediatric oncology patients. She is co-PI of the Children’s Oncology Group study, “A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL.”

Mark Minden, PhD, MD, FRCPC
Staff Physician/Senior Scientist,
Princess Margaret Cancer Centre, Toronto, ON
Orsino Chair in Leukemia Research
Professor, University of Toronto

Dr. Minden grew up in Hamilton where he was introduced to hematology at the Zipursky house. He graduated from U of T medical school in 1974. Following residency in Toronto he undertook a PhD with Drs. Till and McCulloch in cell biology/leukemia research. Subsequently Dr. Minden moved to Boston where he was a clinical oncology fellow under Tom Frei at the Sidney Farber Cancer Center and a basic research fellow with David Housman at MIT. In 1982 he returned to the Princess Margaret Hospital/Ontario Cancer Institute as a clinician scientist. Dr. Minden’s laboratory research has focused on genetic changes in AML and ALL cells, and the identification of novel agents to kill leukemic cells. Dr. Minden is director of the leukemia live cell tissue bank that provides cells to researchers throughout Toronto and around the world. In the clinic, Dr. Minden is involved in the treatment of AML and ALL in young and older adults. With Dr. Joe Brandwein, he adapted the successful pediatric DFCI ALL protocol for use in patients age 18 and older; this is now the standard of care at the Princess Margaret. Dr. Minden works with the AYA program to follow patients post-SickKids treatment.

Comments are closed.